ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Ipsen will acquire Clementia for rare-disease therapies

by Rick Mullin
March 1, 2019 | APPEARED IN VOLUME 97, ISSUE 9

 

Ipsen will acquire the Montreal-based rare-disease specialist Clementia Pharmaceuticals in a deal valued at up to $1.3 billion. The deal will net the French drugmaker palovarotene, which it expects to submit for US Food and Drug Administration approval later this year. The small molecule is a retinoic acid receptor gamma (RARγ) selective agonist being developed to treat two rare bone disorders and other diseases.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment